GlassScriptPhysician profile
Mansi Amin
NPI 1780882852
$2,327.67
in general payments reported to CMS, 2019-2025
18 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $88.80 · 2024: $807 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $457.72 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $250.04 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $246.27 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $228.47 | 2024-2025 | Voquezna |
| Amgen INC. | $189.56 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $179.58 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $175.09 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $118.40 | 2019 | |
| Exact Sciences Corporation | $108.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $97.80 | 2024-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $72.42 | 2024-2025 | Gemtesa |
| Pfizer INC. | $50.01 | 2024-2025 | |
| Inspire Medical Systems, INC. | $47.22 | 2025 | Inspire |
| Verona Pharma, INC. | $42.09 | 2025 | Ohtuvayre |
| Collegium Pharmaceutical, INC. | $17.61 | 2024 | Belbuca |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.07 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $14.93 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $14.76 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansi Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.